Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Belantamab mafodotin
(D11595)		[1] Belantamab mafodotin[1] Belantamab mafodotin (D11595) 💬[10] TNFRSF17,
TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		[12] Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬[1] 28 💬
2Belantamab mafodotin 1.9 mg/kg (8 weeks)
(D11595)		[1] Belantamab mafodotin[1] Belantamab mafodotin (D11595) 💬[10] TNFRSF17,
TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		[12] Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬[1] 28 💬
3Belantamab mafodotin 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks or 8 weeks as determined by Part 1 recommended dosages
(D11595)		[1] Belantamab mafodotin[1] Belantamab mafodotin (D11595) 💬[10] TNFRSF17,
TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		[12] Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬[1] 28 💬
4Belantamab mafodotin 2.5 mg/kg (4 weeks)
(D11595)		[1] Belantamab mafodotin[1] Belantamab mafodotin (D11595) 💬[10] TNFRSF17,
TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		[12] Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬[1] 28 💬
5Belantamab mafodotin 2.5 mg/kg (6 weeks)
(D11595)		[1] Belantamab mafodotin[1] Belantamab mafodotin (D11595) 💬[10] TNFRSF17,
TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		[12] Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬[1] 28 💬
6Belantamab mafodotin 2.5 mg/kg (8 weeks)
(D11595)		[1] Belantamab mafodotin[1] Belantamab mafodotin (D11595) 💬[10] TNFRSF17,
TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		[12] Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬[1] 28 💬